Nombre del producto:2-Chloroethyl chloroformate

IUPAC Name:2-chloroethyl carbonochloridate

CAS:627-11-2
Fórmula molecular:C3H4Cl2O2
Pureza:95%+
Número de catálogo:CM383952
Peso molecular:142.96

Unidad de embalaje Stock disponible Precio($) Cantidad
CM383952-500g 1-2 Weeks ŢĽ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :627-11-2
Fórmula molecular:C3H4Cl2O2
Punto de fusión:-
Código de sonrisas:ClCCOC(Cl)=O
Densidad:
Número de catálogo:CM383952
Peso molecular:142.96
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Erdafitinib
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on September 8, 2023, that it had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) to seek approval of Erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, with disease progression during or following at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-[L]1) inhibitor.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.